利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.017 秒)

    Fatty acid binding proteins as drug targets for endocannabinoids
    3.
    发明授权
    Fatty acid binding proteins as drug targets for endocannabinoids 有权
    脂肪酸结合蛋白作为内源性大麻素的药物靶标

    公开(公告)号：US08980820B2

    公开(公告)日：2015-03-17

    申请号：US13145058

    申请日：2010-01-19

    申请人： Dale Deutsch ,  Martin Kaczocha ,  Sherrye Glaser

    发明人： Dale Deutsch ,  Martin Kaczocha ,  Sherrye Glaser

    IPC分类号： A01N61/00 ,  A01N37/18 ,  G01N33/94

    CPC分类号： G01N33/948 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10

    摘要： The invention provides a method of modulating the level of an endocannabinoid in a subject in need thereof comprising administering an effective amount of an agent that inhibits the interaction of the endocannabinoid with an intracellular fatty acid binding protein (FABP). The invention also provides a method of identifying an agent for modulating the level of an endocannabinoid in a subject comprising testing the agent for its ability to modulate binding of the endocannabinoid with an intracellular FABP. The invention also provides a method of identifying an agent for modulating the level of an endocannabinoid in a subject comprising testing the agent for its ability to modulate expression of an intracellular FABP. The invention also provides a method of identifying an agent for treatment of a neurological disorder comprising testing the agent for its ability to modulate the interaction of an endocannabinoid with an intracellular FABP. The invention also relates to modulation of levels of fatty acid amides for treatment or amelioration of diseases or disorders by modulating binding of the fatty acid amides to fatty acid binding proteins. In one embodiment, the fatty acid binding protein is one or more of FABP3, FABP5, and FABP7. In one embodiment, the level of an endocannabinoid is modulated.

    摘要翻译： 本发明提供调节有需要的受试者中内源性大麻素水平的方法，包括施用有效量的抑制内源性大麻素与细胞内脂肪酸结合蛋白（FABP）相互作用的药剂。 本发明还提供了鉴定用于调节受试者中内源性大麻素水平的药剂的方法，包括测试该药剂调节内源性大麻素与细胞内FABP结合的能力。 本发明还提供了鉴定用于调节受试者中内源性大麻素水平的药剂的方法，所述方法包括测试所述药剂调节细胞内FABP表达的能力。 本发明还提供鉴定用于治疗神经障碍的药剂的方法，其包括测试该药剂调节内源性大麻素与细胞内FABP相互作用的能力。 本发明还涉及通过调节脂肪酸酰胺与脂肪酸结合蛋白的结合来调节用于治疗或改善疾病或病症的脂肪酸酰胺的水平。 在一个实施方案中，脂肪酸结合蛋白是FABP3，FABP5和FABP7中的一种或多种。 在一个实施方案中，调节内源性大麻素的水平。

    COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANES FOR TREATMENT OF CANCER
    4.
    发明申请
    COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANES FOR TREATMENT OF CANCER 有权

    公开(公告)号：US20230017948A1

    公开(公告)日：2023-01-19

    申请号：US17779214

    申请日：2020-11-24

    申请人： Iwao OJIMA ,  Martin Martin KACZOCHA ,  Gregory CARBONETTI ,  The Research Foundation for The State University of New York

    发明人： Iwao Ojima ,  Martin Kaczocha ,  Gregory Carbonetti

    IPC分类号： A61K31/216 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00 ,  C07C69/757

    摘要： This invention provides a method of treating a subject afflicted with a cancer comprising periodically administering to the subject an amount of a FABP5 inhibitor and an amount of an anticancer therapy, wherein the amounts when taken together are effective to treat the subject. This invention also provides FABP5 inhibitors for use as an add-on therapy or in combination with an anticancer therapy or in treating a subject afflicted with a cancer. This invention also provides the use of a FABP5 inhibitor in the manufacturing of a medicament for use in combination or as an add on with an anticancer therapy in treating a subject afflicted with cancer, wherein the FABP5 inhibitor and the anticancer therapy are administered simultaneously, contemporaneously or concomitantly. This invention also provides a pharmaceutical composition comprising an amount of a FABP5 inhibitor and an amount of an anticancer therapy for use in treating a subject afflicted with a cancer, wherein the FABP5 inhibitor and an anticancer therapy are administered sequentially or simultaneously.

    FATTY ACID BINDING PROTEINS AS DRUG TARGETS FOR ENDOCANNABINOIDS
    8.
    发明申请
    FATTY ACID BINDING PROTEINS AS DRUG TARGETS FOR ENDOCANNABINOIDS 有权
    脂肪酸结合蛋白作为内给药的药物目标

    公开(公告)号：US20120165388A1

    公开(公告)日：2012-06-28

    申请号：US13145058

    申请日：2010-01-19

    申请人： Dale Deutsch ,  Martin Kaczocha ,  Sherrye Glaser

    发明人： Dale Deutsch ,  Martin Kaczocha ,  Sherrye Glaser

    IPC分类号： A61K31/7088 ,  A61P25/00 ,  A61K31/713 ,  G01N33/566

    CPC分类号： G01N33/948 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10

    摘要： The invention provides a method of modulating the level of an endocannabinoid in a subject in need thereof comprising administering an effective amount of an agent that inhibits the interaction of the endocannabinoid with an intracellular fatty acid binding protein (FABP). The invention also provides a method of identifying an agent for modulating the level of an endo cannabinoid in a subject comprising testing the agent for its ability to modulate binding of the endocannabinoid with an intracellular FABP. The invention also provides a method of identifying an agent for modulating the level of an endocannabinoid in a subject comprising testing the agent for its ability to modulate expression of an intracellular FABP. The invention also provides a method of identifying an agent for treatment of a neurological disorder comprising testing the agent for its ability to modulate the interaction of an endocannabinoid with an intracellular FABP. The invention also relates to modulation of levels of fatty acid amides for treatment or amelioration of diseases or disorders by modulating binding of the fatty acid amides to fatty acid binding proteins. In one embodiment, the fatty acid binding protein is one or more of FABP3, FABP5, and FABP7. In one embodiment, the level of an endocannabinoid is modulated.

    摘要翻译： 本发明提供调节有需要的受试者中内源性大麻素水平的方法，包括施用有效量的抑制内源性大麻素与细胞内脂肪酸结合蛋白（FABP）相互作用的药剂。 本发明还提供鉴定用于调节受试者中内毒素大麻素水平的试剂的方法，包括测试试剂调节内源性大麻素与细胞内FABP结合的能力。 本发明还提供了鉴定用于调节受试者中内源性大麻素水平的药剂的方法，所述方法包括测试所述药剂调节细胞内FABP表达的能力。 本发明还提供鉴定用于治疗神经障碍的药剂的方法，其包括测试该药剂调节内源性大麻素与细胞内FABP相互作用的能力。 本发明还涉及通过调节脂肪酸酰胺与脂肪酸结合蛋白的结合来调节用于治疗或改善疾病或病症的脂肪酸酰胺的水平。 在一个实施方案中，脂肪酸结合蛋白是FABP3，FABP5和FABP7中的一种或多种。 在一个实施方案中，调节内源性大麻素的水平。